CTS Detachable Dynabeads CD3/CD28 Provides One-Step Isolation And Activation With Flexible Active Release To Optimize T Cell Phenotype

The Gibco™ CTS™ Dynabeads™ CD3/CD28 technology, clinically approved CAR T cell therapy, has been developed further to improve treatment outcomes. The new Gibco™ CTS™ Release Buffer and Detachable Dynabeads™ CD3/CD28 (active-release beads) allow for termination of activation signaling at any time, preserving an early T cell phenotype and shortening the T cell manufacturing process. The studies featured here show that the active-release beads maintained a comparable early memory phenotype and achieved a near 20-fold average cell expansion by day 7 and near 60-fold or higher by day 10. This development could improve the reliability, consistency, and longevity of cell therapy treatments.